Next Article in Journal
Metabolic and Physiological Responses of Shiraz and Cabernet Sauvignon (Vitis vinifera L.) to Near Optimal Temperatures of 25 and 35 °C
Next Article in Special Issue
Long Non-Coding RNAs in Endometrial Carcinoma
Previous Article in Journal
Inhibitory Effect of Dried Pomegranate Concentration Powder on Melanogenesis in B16F10 Melanoma Cells; Involvement of p38 and PKA Signaling Pathways
Previous Article in Special Issue
Long Non-Coding RNAs as Master Regulators in Cardiovascular Diseases
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(10), 24243-24275; doi:10.3390/ijms161024243

The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients

1
Department of Pathology, Stavanger University Hospital, Gerd Ragna Bloch Thorsens Gate 8, 4011 Stavanger, Norway
2
Department of Mathematics and Natural Sciences, University of Stavanger, 4036 Stavanger, Norway
3
Department of Breast and Endocrine Surgery, Stavanger University Hospital, 4011 Stavanger, Norway
4
Department of Clinical Science, University of Bergen, Postboks 7804, 5020 Bergen, Norway
5
Department of Clinical Epidemiology, Aarhus University, Science Center Skejby, Olof Palmes Allé 43, Aarhus N, 8200 Aarhus, Denmark
6
Department of Haematology and Oncology, Stavanger University Hospital, Gerd Ragna Bloch Thorsens Gate 8, 4011 Stavanger, Norway
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Academic Editor: Martin Pichler
Received: 8 September 2015 / Revised: 28 September 2015 / Accepted: 30 September 2015 / Published: 14 October 2015
(This article belongs to the Collection Regulation by Non-Coding RNAs)
View Full-Text   |   Download PDF [2752 KB, uploaded 14 October 2015]   |  

Abstract

Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers that may be used to monitor predictors of treatment response. MicroRNAs are promising biomarkers that may fill the gap between preclinical knowledge and clinical observations regarding endocrine resistance. MicroRNAs regulate gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in the primary tumor, but also in the circulation of breast cancer patients. The few available studies investigating microRNA in patients suggest that seven microRNAs (miR-10a, miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact more readily with estrogen receptor (ER)-independent pathways than ER-related signaling pathways. Some of these pathways are targetable (e.g., PIK3CA), suggesting that microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of the role of these candidate microRNAs in large prospective studies is warranted. View Full-Text
Keywords: breast cancer; tamoxifen; endocrine resistance; microRNA; biomarker breast cancer; tamoxifen; endocrine resistance; microRNA; biomarker
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Egeland, N.G.; Lunde, S.; Jonsdottir, K.; Lende, T.H.; Cronin-Fenton, D.; Gilje, B.; Janssen, E.A.M.; Søiland, H. The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Int. J. Mol. Sci. 2015, 16, 24243-24275.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top